Skip to main content

Table 2 Clinicopathological data association with CDX2, MUC2 and SOX2 status in 227 patients with stage II colorectal carcinoma

From: Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients

  CDX2 MUC2 SOX2
Low High P Low High P + P
Patients 33 194 164 63 184 43
Age (years)
 Media 67.7 ± 11.8 68.4 ± 11.4 0.81 68.3 ± 11.7 68.2 ± 11.1 0.96 67.9 ± 11.5 69.9 ± 11.1 0.74
 Range 35–87 23–92 23–92 37–83 23–92 37–87
Sex
 Female 19 73 0.04* 65 27 0.65 72 20 0.39
 Male 14 121 99 36 112 23
Histopathological grade (n = 224; ND = 3)
 G1 0 4 < 0.001* 1 3 0.05 3 1 0.20
 G2 25 185 157 53 173 37
 G3 7 3 6 4 6 4
Tumor Location (n = 224; ND = 3)
 Proximal colon 16 59 0.09 48 27 0.13 58 17 0.22
 Distal colon 14 93 83 24 92 15
 Rectum 3 39 30 12 32 10
Mismatch repair status (n = 209; ND = 18)
 MMR-deficient 22 69 < 0.001* 68 23 0.75 77 14 0.37
 MMR-proficient 7 111 85 33 93 25
BRAFV600E (n = 216; ND = 11)
 WT 25 161 0.17 132 54 1.00 152 34 0.80
 MUT 7 23 21 9 24 6
CDX2
 Low   23 10 0.83 26 7 0.81
 High 141 53 158 36
MUC2
 Low    137 27 0.13
 High 47 16
  1. Notes. It is indicated the number of cases with low and high expression of CDX2 and MUC2 and negative (−) or positive (+) for SOX2, for all the clinicopathological categories, except age. P values (statistical significance threshold< 0.05) were obtained using Student’s t test for the continuous variable, Fisher’s exact test (2-sided) and Qui-square (χ2) test for categorical variables
  2. * indicates comparisons with P < 0.05
\